Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Maze Therapeutics to “Sell” from “Hold,” although the broader analyst consensus remains “Buy” with an average price target of $66.
• Maze shares opened at $27.18, down 1.8%, well below their 52-week high of $53.65. The company remains unprofitable, reporting a quarterly loss of $0.76 per share and facing an expected full-year loss of $2.74 per share.
• Insiders sold 140,674 shares worth about $3.9 million over the past 90 days under pre-arranged trading plans, while the company continues to receive support from some analysts and institutional investors.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday.

A number of other equities analysts also recently commented on the stock. Weiss Ratings reissued a "sell (d-)" rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. BTIG Research reaffirmed a "buy" rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Maze Therapeutics presently has an average rating of "Buy" and a consensus target price of $66.00.

Maze Therapeutics Trading Down 1.8%

NASDAQ MAZE opened at $27.18 on Friday. Maze Therapeutics has a one year low of $12.81 and a one year high of $53.65. The company's 50 day moving average price is $27.79 and its 200 day moving average price is $33.03. The company has a debt-to-equity ratio of 0.09, a quick ratio of 17.88 and a current ratio of 18.31. The firm has a market capitalization of $1.51 billion, a price-to-earnings ratio of -10.79 and a beta of 2.21.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.76) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.76). On average, sell-side analysts predict that Maze Therapeutics will post -2.74 EPS for the current year.

Insider Buying and Selling at Maze Therapeutics

In other news, CMO Harold Bernstein sold 16,142 shares of the business's stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62. Following the transaction, the chief marketing officer directly owned 16,142 shares of the company's stock, valued at approximately $445,680.62. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the company's stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $27.34, for a total transaction of $205,050.00. Following the completion of the transaction, the insider owned 26,250 shares of the company's stock, valued at $717,675. This trade represents a 22.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 140,674 shares of company stock valued at $3,904,707 over the last 90 days. 5.30% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Maze Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada increased its position in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company's stock worth $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Maze Therapeutics during the fourth quarter worth about $39,000. Ameritas Investment Partners Inc. lifted its position in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after purchasing an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Maze Therapeutics in the fourth quarter worth about $43,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new stake in Maze Therapeutics in the second quarter valued at about $48,000.

Key Stories Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: BTIG issued a Buy rating. The endorsement adds to the constructive analyst view of Maze’s pipeline and could support investor confidence. Maze Therapeutics Earns Buy Rating from BTIG Research
• Positive Sentiment: Maze strengthened its board with two experienced executives. Paula Johnson, M.D., M.P.H., and Sophie Kornowski, Pharm.D., M.B.A., bring extensive clinical, pharmaceutical, partnering, and commercialization expertise. Management also highlighted additional MZE829 data in late 2026 or early 2027, initial MZE782 data in 2027, and additional trial starts next year. Maze Therapeutics Announces Appointments to Its Board of Directors
• Positive Sentiment: HC Wainwright raised all of its reported EPS forecasts. Estimates improved for third-quarter 2026, fourth-quarter 2026, and fiscal years 2026 through 2030. For example, FY2026 EPS was revised to a loss of $2.81 from $2.96, while FY2030 was revised to a loss of $0.72 from $0.74, indicating expectations for a somewhat faster reduction in losses over time.
• Neutral Sentiment: Maze reported second-quarter 2026 financial results and recent business highlights. The available report headline does not provide the detailed financial figures, so the earnings release’s impact cannot be fully assessed from the supplied information. Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
• Negative Sentiment: Maze remains unprofitable. HC Wainwright’s revised forecasts still call for substantial losses through 2030, and its FY2026 estimate of a $2.81 loss is slightly worse than the $2.73 consensus forecast.
• Negative Sentiment: Reported insider activity is a concern. Company insiders have recorded sales but no purchases during the past six months, potentially weighing on sentiment.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source